Kurs
+7,27%
Kurs
+7,27%
Open
25,19
High
27,08
Low
24,95
Close
26,23
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Kalender
| Tid* | ||
| 2026-03-05 | 06:00 | Bokslutskommuniké 2025 |
| 2025-11-26 | 06:00 | Kvartalsrapport 2025-Q3 |
| 2025-09-17 | 06:00 | Kvartalsrapport 2025-Q2 |
| 2025-06-25 | N/A | Årsstämma |
| 2025-06-10 | 06:00 | Kvartalsrapport 2025-Q1 |
| 2025-03-05 | 06:00 | Bokslutskommuniké 2024 |
| 2024-12-20 | - | Extra Bolagsstämma 2024 |
| 2024-11-27 | - | Kvartalsrapport 2024-Q3 |
| 2024-09-12 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-28 | - | Kvartalsrapport 2024-Q1 |
| 2024-06-27 | - | X-dag ordinarie utdelning SOFTX 0.00 NOK |
| 2024-06-26 | - | Årsstämma |
| 2024-03-20 | - | Bokslutskommuniké 2023 |
| 2023-10-26 | - | Kvartalsrapport 2023-Q3 |
| 2023-09-26 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-21 | - | Årsstämma |
| 2023-06-21 | - | Kvartalsrapport 2023-Q1 |
| 2023-03-30 | - | X-dag ordinarie utdelning SOFTX 0.00 NOK |
| 2023-02-17 | - | Bokslutskommuniké 2022 |
| 2022-12-09 | - | Extra Bolagsstämma 2022 |
| 2022-10-26 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-15 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-28 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-19 | - | X-dag ordinarie utdelning SOFTX 0.00 NOK |
| 2022-04-17 | - | Årsstämma |
| 2022-02-16 | - | Bokslutskommuniké 2021 |
| 2021-12-29 | - | Extra Bolagsstämma 2021 |
| 2021-11-17 | - | Kvartalsrapport 2021-Q3 |
| 2021-09-08 | - | Kvartalsrapport 2021-Q2 |
| 2021-04-29 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-14 | - | X-dag ordinarie utdelning SOFTX 0.00 NOK |
| 2021-04-13 | - | Årsstämma |
| 2021-02-09 | - | Bokslutskommuniké 2020 |
| 2020-12-14 | - | Kvartalsrapport 2020-Q3 |
| 2020-09-30 | - | Kvartalsrapport 2020-Q2 |
| 2020-07-01 | - | X-dag ordinarie utdelning SOFTX 0.00 NOK |
| 2020-06-30 | - | Årsstämma |
| 2020-06-30 | - | Kvartalsrapport 2020-Q1 |
| 2019-12-20 | - | Extra Bolagsstämma 2019 |
| 2019-06-27 | - | Årsstämma |
| 2019-06-03 | - | X-dag ordinarie utdelning SOFTX 0.00 NOK |
| 2018-07-02 | - | Split SOFTX 1:50 |
Beskrivning
| Land | Norge |
|---|---|
| Lista | Euronext Growth Oslo |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2021-10-19 14:36:59
(SoftOx) We are pleased to announce that the first patient has been recruited to
the SBE-01 clinical study. After having experienced unforeseen challenges
regarding access to and availability of eligible patients, mainly due to the
nationwide nurse strike in Denmark, it is reassuring that the study team has now
been able to screen and select several patients for the study, says Glenn
Gundersen, Chief Medical Officer in SoftOx Solutions.
SBE-01 (EudraCT no. 2021-000314-42) is the first-in-man (phase I) study with the
SoftOx' lead wound care product, SBE, designed to treat infected chronic wounds.
The study will establish a tolerable dose and treatment schedule for SBE to be
able to develop it into an effective infection-treatment solution in
problematic, non-healing wounds.
For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CMO, Glenn Gundersen
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599
About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com